Barclays PLC Axcella Health Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.06 - $3.61 $4,770 - $8,360	-2,316 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.98 - $4.31 $2,559 - $3,702	-859 Reduced 27.06%	2,316 $7,000
Q2 2021 Aug 13, 2021	SELL	$3.08 - $5.13 $30,088 - $50,114	-9,769 Reduced 75.47%	3,175 $13,000
Q1 2021 May 13, 2021	BUY	$4.55 - $6.72 $36,154 - $53,397	7,946 Added 158.98%	12,944 $62,000
Q4 2020 Feb 11, 2021	SELL	$4.24 - $5.97 $7,729 - $10,883	-1,823 Reduced 26.73%	4,998 $26,000
Q3 2020 Nov 12, 2020	BUY	$4.12 - $5.91 $6,126 - $8,788	1,487 Added 27.88%	6,821 $31,000
Q2 2020 Aug 12, 2020	BUY	$2.94 - $7.7 $7,973 - $20,882	2,712 Added 103.43%	5,334 $30,000
Q1 2020 May 13, 2020	SELL	$2.25 - $5.24 $11,655 - $27,143	-5,180 Reduced 66.39%	2,622 $9,000
Q4 2019 Feb 10, 2020	BUY	$3.08 - $5.9 $19,585 - $37,518	6,359 Added 440.68%	7,802 $31,000
Q3 2019 Nov 14, 2019	SELL	$5.25 - $9.26 $27,552 - $48,596	-5,248 Reduced 78.43%	1,443 $9,000
Q2 2019 Aug 14, 2019	BUY	$8.51 - $14.95 $56,940 - $100,030	6,691 New	6,691 $62,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.